comparemela.com
Home
Live Updates
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases : comparemela.com
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability
Related Keywords
Singapore ,
Enleofen Bio Pte ,
Stuart Cook ,
Cliver Wood ,
Linda Ruckel ,
Reinhard Malin ,
Jeffrey Lu ,
Andrew Khoo ,
Boehringer Ingelheim ,
National Heart Centre Singapore At Singhealth ,
Cardiovascular Metabolic Disorders Programme At ,
Animal Health ,
Tanoto Foundation Professor Of Cardiovascular Medicine ,
Academic Medical Centre ,
Enleofen Bio ,
Corporate Senior Vice President ,
Global Head ,
Discovery Research ,
Prof Stuart Cook ,
Tanoto Foundation Professor ,
Cardiovascular Medicine ,
Medical Centre ,
Cardiovascular Metabolic Disorders Programme ,
Human Pharma ,
Sebastian Sch ,
National Heart Centre Singapore ,
Gefallene Big Techs ,
Boehringer ,
Ingelheim ,
Egins ,
Linical ,
Development ,
First ,
Glass ,
Treatment ,
Fibrotic ,
Diseases ,
comparemela.com © 2020. All Rights Reserved.